Across TCGA pan-cancer cohorts, TRAV13-2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated TRAV13-2 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher TRAV13-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAV13-2 expression acts as an unfavorable survival marker.

STAD, UCEC, and SKCM are the cancer types where TRAV13-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	DFS	Median	All	0.089	0.657	<.001	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	All	0.111	0.327	.008	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: TRAV13-2 tumor-vs-normal RNA expression · all TRAV13-2 data types